Influence of GeneXpert MRSA/SA test implementation on clinical outcomes of Staphylococcus aureus bacteremia - a before-after retrospective study.


Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
02 2019
Historique:
received: 30 06 2018
revised: 18 08 2018
accepted: 20 08 2018
pubmed: 23 9 2018
medline: 22 3 2019
entrez: 23 9 2018
Statut: ppublish

Résumé

Use of GeneXpert MRSA/SA in diagnostic algorithms of Staphylococcus aureus bacteremia may influence both patients' clinical outcomes and antibiotic stewardship. We evaluated these outcomes in a retrospective cohort before (1/6/2015-31/5/2016) and after (1/6/2016-31/8/2017) the introduction of the test in adult patients with Gram-positive cocci in clusters in blood cultures. We included 254 patients (125 preintervention, 129 postintervention). No significant difference in 30-day mortality or clinical success was demonstrated between periods. Appropriate antibiotic therapy rates were significantly higher in the postintervention group, and vancomycin use was significantly reduced (80.6% vs 53.6%, P < 0.01; 2.3±0.38 vs 2.98±1.02 defined daily doses/100 patient days, P = 0.026, respectively). Appropriate beta-lactam use was also significantly higher (56.7% postintervention vs 23.1% preintervention, P < 0.01). Use of GeneXpert MRSA/SA test has a positive effect on antibiotic stewardship measures, though it has no significant effect on clinical outcomes including mortality in this fatal infection.

Identifiants

pubmed: 30241971
pii: S0732-8893(18)30305-5
doi: 10.1016/j.diagmicrobio.2018.08.011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-124

Commentaires et corrections

Type : ErratumIn
Bisahra J [corrected to Bishara J]

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Haim Ben-Zvi (H)

Microbiology Laboratory, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Genady Drozdinsky (G)

Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel.

Shiri Kushnir (S)

Research and Development Unit, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel.

Tomer Avni (T)

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel.

Oded Scheuerman (O)

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Pediatric Infectious Diseases Unit, Schneider Children's Medical Center of Israel.

Jihad Bisahra (J)

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel.

Dafna Yahav (D)

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel. Electronic address: dafna.yahav@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH